ClinicalTrials.gg
CompletedNCT03336593Updated Apr 2, 2019

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

A Phase 2 interventional study of Quadrivalent Influenza Vaccine and Trivalent Influenza Vaccine in Safety Issues, sponsored by PT Bio Farma. Completed at 3 sites in Indonesia. Open to participants aged 6 Months to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-02.

Sponsored by PT Bio Farma · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
6 Months to 40 Years
Sex
All
01

Study summary

This study is to assess protectivity and safety of Quadrivalent Influenza Vaccine in Indonesian Population

Read the detailed description

To describe the protectivity rate of Quadrivalent Influenza HA vaccine 28 days after immunization in Indonesian population.

To describe immunogenicity of quadrivalent Influenza HA vaccine in all subjects

02

Conditions studied

  • Safety Issues
03

In context

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Subjects 9 - 40 Years of Age:

  • Healthy
  • Properly informed about the study and having signed the form
  • Subject/Parent will commit themselves to comply with the instructions of the investigator and the schedule of the trial.

Inclusion Criteria for Subjects 6 Months - 8 Years of Age:

  • Healthy
  • Parents have been informed properly regarding the study and signed the informed consent form
  • Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial

Exclusion Criteria:

  • Subject concomitantly enrolled or scheduled to be enrolled in another trial
  • Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature >= 37.5 C )
  • Known history of allergy to egg and or chicken protein or any component of the vaccines
  • History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection
  • Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (> 2 weeks).
  • Pregnancy \& Lactation (Adult)
  • Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives
  • Subject already immunized with influenza vaccine within 1 year.
  • Subjects receive any vaccination within 1 month before and after immunization of Quadrivalent Influenza Vaccine.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
810 participants (actual)

Study arms

  • Experimental
    QIV batch 1

    1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1

    Biological: Quadrivalent Influenza Vaccine

  • Experimental
    QIV batch 2

    1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2

    Biological: Quadrivalent Influenza Vaccine

  • Experimental
    QIV batch 3

    1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3

    Biological: Quadrivalent Influenza Vaccine

  • Active comparator
    Trivalent Influenza Vaccine

    1 dose of 0.5 ml of trivalent influenza vaccine

    Biological: Trivalent Influenza Vaccine

  • Experimental
    QIV (subjects 6-35 months)

    2 dose of 0.25 ml of quadrivalent influenza vaccine

    Biological: Quadrivalent Influenza Vaccine

  • Experimental
    QIV (subjects 3-8 years)

    2 dose of 0.5 ml of quadrivalent influenza vaccine

    Biological: Quadrivalent Influenza Vaccine

Interventions

  • BiologicalQuadrivalent Influenza Vaccine

    1 or 2 doses of Quadrivalent Influenza Vaccine depends on age

    Also known as: QIV

  • BiologicalTrivalent Influenza Vaccine

    1 dose of Trivalent Influenza Vaccine

    Also known as: TIV

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with an anti-influenza titer >= 1:40 HI units

    The anti-influenza antibody serological response

    Time frame: 28 days after the last dose immunization

Secondary outcomes

  1. Geometric Mean Titer (GMT)

    GMT in all subjects; comparison of GMT between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison of GMT between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old

    Time frame: 28 days

  2. Percentage of subjects with increasing antibody titer >= 4 times

    Percentage of subjects with increasing antibody titer \>= 4 times: in all subjects; comparison between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old

    Time frame: 28 days

  3. Percentage of subjects with transition of seronegative to seropositive

    Percentage of subjects with transition of seronegative to seropositive: in all subjects; comparison between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old

    Time frame: 28 days

  4. Percentage of subjects with at least one immediate reaction

    Immediate reaction (local reaction or systemic event)

    Time frame: 30 minutes after each vaccination

  5. Percentage of subjects with at least one of these adverse events

    At least one of these adverse events, expected or not

    Time frame: within 72 hours, between 72 hours to 28 days after vaccination

  6. Serious adverse event after vaccination

    Serious adverse event occurring from inclusion until 28 days after vaccination.

    Time frame: 28 days

  7. Comparison adverse events between quadrivalent and trivalent influenza HA vaccine.

    Adverse events occuring until 28 days after vaccination

    Time frame: 28 days

  8. Comparison of adverse events between each batch number of quadrivalent influenza HA vaccine.

    Adverse events occuring until 28 days after vaccination

    Time frame: 28 days

07

Study locations

3 sites
  • Garuda Primary Health Center
    Bandung, West Java, Indonesia
  • Ibrahim Adjie Primary Health Center
    Bandung, West Java, Indonesia
  • Puter Primary Health Center
    Bandung, West Java, Indonesia
08

References and documents

Publications

  • Dhamayanti M, Tarigan R, Fadlyana E, Prasetyo D, Amalia N, Rusmil VK, Sari RM, Bachtiar NS, Rusmil K, Kartasasmita CB. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study. Vaccine. 2020 Jan 29;38(5):993-1000. doi: 10.1016/j.vaccine.2019.12.008. Epub 2019 Dec 17. PubMed 31862195 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 8, 2017
StartActual
Nov 21, 2017
Primary completionActual
Mar 14, 2018
CompletionActual
Nov 30, 2018
Last update
Apr 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03336593
Lead sponsor
PT Bio Farma
Responsible party
Sponsor
First posted
Nov 8, 2017
Start date
Nov 21, 2017
Primary completion
Mar 14, 2018
Completion
Nov 30, 2018
Last update
Apr 2, 2019

Study contacts

Meita Dhamayanti
principal investigator · Hasan Sadikin General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion